• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by QuidelOrtho Corporation

    5/22/25 4:05:30 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $QDEL alert in real time by email
    SD 1 qdelformsd2024.htm SD Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549
    FORM SD
    Specialized Disclosure Report
    QUIDELORTHO CORPORATION
    (Exact Name of the Registrant as Specified in its Charter)
    Delaware
    001-41409
    87-4496285
    (State or Other Jurisdiction of Incorporation or Organization)
    (Commission File Number)
    (I.R.S. Employer Identification No.)
    9975 Summers Ridge Road, San Diego, CA 92121
    (Address of Principal Executive Offices) (Zip Code)
    Joseph M. Busky, Chief Financial Officer
    (858) 552-1100
    (Name and telephone number, including area code, of the person to contact in connection with this report.)

    Check the appropriate box to indicate the rule pursuant to which this Form is being submitted, and provide the period to which the information in this Form applies:
    x
    Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024.
    ☐Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended ___.





    Section 1 - Conflict Minerals Disclosure
    Item 1.01    Conflict Minerals Disclosure and Report
    QuidelOrtho Corporation has filed a Conflict Minerals Report, which is attached as Exhibit 1.01 hereto. The Conflict Minerals Report is also publicly available at www.quidelortho.com through the “Investor Relations” link. The content of any website referred to in this Form SD is included for general information only and is not incorporated by reference in this Form SD.
    Item 1.02    Exhibit
    The Conflict Minerals Report for the calendar year ended December 31, 2024 is filed as Exhibit 1.01 hereto.
    Section 2 - Resource Extraction Issuer Disclosure
    Item 2.01    Resource Extraction Issuer Disclosure and Report
    Not applicable.
    Section 3 - Exhibits
    Item 3.01    Exhibits
    Exhibit 1.01    Conflict Minerals Report as required by Items 1.01 and 1.02 of Form SD.




    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.
    Date: May 22, 2025
     
       
      QUIDELORTHO CORPORATION
    (Registrant)
      
    By:/s/ Joseph M. Busky
    Name:Joseph M. Busky
    Title:Chief Financial Officer



    Get the next $QDEL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $QDEL

    DatePrice TargetRatingAnalyst
    5/8/2025$44.00Hold → Buy
    Jefferies
    12/11/2024$44.00 → $50.00Neutral → Buy
    Citigroup
    12/10/2024$43.00Hold
    Jefferies
    9/19/2024$42.00 → $50.00Neutral
    UBS
    9/5/2024$40.00 → $57.00Hold → Buy
    Craig Hallum
    3/4/2024$70.00 → $42.00Neutral → Sell
    UBS
    2/14/2024$66.00 → $37.00Neutral → Underweight
    JP Morgan
    12/11/2023$95.00 → $72.00Buy → Neutral
    Citigroup
    More analyst ratings

    $QDEL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • QuidelOrtho Announces Strategy to Accelerate Growth in Molecular Diagnostics

      ―Company Intends to Acquire LEX Diagnostics Upon U.S. FDA Clearance――Company Plans to Discontinue Savanna® Platform Development――Company Reaffirms Full Year 2025 Financial Guidance ――Company to Host Conference Call Today at 5:00 p.m. ET― SAN DIEGO, June 3, 2025 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs, and transfusion medicine, today announced a refocusing of its molecular diagnostics strategy. This strategy includes the intent to acquire full ownership of LEX Diagnostics after 510(k) clearance by the U.S. Food and Drug Administrat

      6/3/25 4:10:00 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • QuidelOrtho to Participate in Upcoming Investor Conferences

      QuidelOrtho Corporation (NASDAQ:QDEL) ("QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will participate in two upcoming investor conferences: William Blair 45th Annual Growth Stock Conference, Wednesday, June 4, 2025 Members of QuidelOrtho's management team will participate in a presentation at 9:00 a.m. ET / 6:00 a.m. PT. Jefferies Global Healthcare Conference, Thursday, June 5, 2025 Members of QuidelOrtho's management team will participate in a fireside chat at 8:45 a.m. ET / 5:45 a.m. PT. Interested parties can access the liv

      5/22/25 4:30:00 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • QuidelOrtho Reports First Quarter 2025 Financial Results

      ― Total revenue of $693 million, growth of 5% as reported and 6% in constant currency, excluding COVID-19 and Donor Screening ― ― Strong execution on cost-savings initiatives driving improved margins and profitability ― ― Company maintains full-year 2025 financial guidance ― First Quarter 2025 Results (all comparisons are to the prior year period) Total revenue was $693 million, as reported Non-respiratory revenue was $573 million, which was flat to the prior year period as reported and an increase of 2% in constant currency Labs revenue grew 5% as reported and 7% in constant currency Donor Screening revenue declined by 62% as the Company continues to wind down the U.S. portion of

      5/7/25 4:05:00 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care